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Abstract
Infantile hepatopathies are life-threatening liver disorders that manifest in the first few months of life. We report on a consanguineous Irish Traveller family that includes six individuals presenting with acute liver failure in the first few months of life. Additional symptoms include anaemia, renal tubulopathy, developmental delay, seizures, failure to thrive and deterioration of liver function with minor illness. The multisystem manifestations suggested a possible mitochondrial basis to the disorder. However, known causes of childhood liver failure and mitochondrial disease were excluded in this family by biochemical, metabolic and genetic analyses. We aimed to identify the underlying risk gene using homozygosity mapping and whole exome sequencing. SNP homozygosity mapping identified a candidate locus at 5q31.3-q33.1. Whole exome sequencing identified 1 novel homozygous missense mutation within the 5q31.3-q33.1 candidate region that segregated with the hepatopathy. The candidate mutation is located in the LARS gene which encodes a cytoplasmic leucyl-tRNA synthetase enzyme responsible for exclusively attaching leucine to its cognate tRNA during protein translation. Knock-down of LARS in HEK293 cells did not impact on mitochondrial function even when the cells were put under physiological stress.
The molecular studies confirm the findings of the patients' biochemical and genetic analyses which show that the hepatopathy is not a mitochondrial-based dysfunction problem, despite clinical appearances. This study highlights the clinical utility of homozygosity mapping and exome sequencing in diagnosing recessive liver disorders. It reports mutation of a cytoplasmic aminoacyl-tRNA synthetase enzyme as a possible novel cause of infantile hepatopathy and underscores the need to consider mutations in LARS in patients with liver disease and multisystem presentations.
Introduction
Infantile liver disease, or hepatopathy, affects approximately 1 in 2,500 live births [1] and can be a life-threatening condition. Liver failure in infancy is challenging to diagnose and manage, and has a high mortality rate [2] . First symptoms usually develop in early infancy and include poor feeding, failure to thrive, vomiting, jaundice, distended abdomen and hypoactivity. Clinically, infantile hepatopathies manifest with elevated liver transaminases, hypoglycemia, cholestasis, coagulopathy and hyperbilirubinemia. Biochemical and genetic investigations can help establish the underlying basis of the hepatopathy. However, the etiology of many liver diseases is not known and a poor understanding of the pathogenesis has hampered the development of improved diagnostic and therapeutic strategies [1] .
Identification of the spectrum of disease-causing genes is crucial to further our understanding of the mechanisms that underlie these complex conditions.
Medical case reports of specific gene defects have been pivotal to our understanding of clinical phenotypes and individual genes that contribute to liver dysfunction [3] . The current study involves an extended Irish Traveller family that includes six individuals with a variable phenotype consisting of infantile liver failure, anaemia, failure to thrive, seizures, moderate developmental delay, renal tubulopathy and deterioration of liver function with minor illness (Fig. 1a and Supplementary Table 1 ). The defining phenotypic feature in this family is infantile liver failure, a rare condition with an estimated prevalence of <1/1,000,000 (Orphanet). The patients show signs of intermittent improvement and only develop acute symptoms when their bodies are under physiologic stress due to illness. The earliest age of presentation was at 2 months and the oldest affected member of this family is now aged 33 years.
Four liver biopsies were obtained from three of the patients. Initial biopsy of patient III:10 at 3 months of age showed a profound, pan-lobular and predominantly macrovesicular steatosis with lobular disarray, hepatocyte ballooning and individual hepatocyte necrosis (Fig. 1b) . A subsequent biopsy at age 4 showed persistent if less pronounced steatosis, now largely confined to periportal region, with the development of bland bridging fibrosis. Biopsies from patient III:4 (Fig. 1c) and IV:1 at age 9 and 16 months respectively showed almost identical patterns of periportal steatosis and early portal fibrosis.
Known metabolic and genetic causes of liver failure, including galactosemia, tyrosinemia, fructose intolerance, peroxisomal and lysosomal disorders, fatty acid oxidation disorders, bile acid disorders, urea cycle disorders, glycogen storage disorders, neonatal hemachromatosis and congenital disorders of glycosylation were excluded through clinical, biochemical and genetic analyses (Supplementary Table 2 ). Due to the multisystem involvement in the patients, a possible mitochondrial basis for the disorder was investigated. Electron microscopy of muscle tissue showed normal mitochondrial appearance. Genetic analyses excluded major mitochondrial rearrangements, including Pearson's deletion, and sequence analysis of mitochondrial DNA did not identify any pathogenic mutations. There was no evidence of a mitochondrial respiratory chain defect in muscle or liver tissues. The patients were assessed for mitochondrial DNA content in muscle and liver tissue but no depletion was found. Two of the common mitochondrial disease genes in the Irish and Irish Traveller populations, POLG1 and SURF1, were sequenced but no causative mutations were identified.
We aimed to identify the underlying disease gene for an infantile hepatopathy using the combined approach of homozygosity mapping and whole exome sequencing.
Materials and Methods

Genotyping and homozygosity mapping
DNA samples from three patients (III:4, III:7 and III:10) and five unaffected relatives (II:5, II:6, II:7, II:8 and III:9) were available for molecular analysis. Ethical approval for the study was obtained from the ethics committee of Our Lady's Children's Hospital, Dublin 12, Ireland. Genomic DNA was extracted from peripheral lymphocytes and genotyped for 1 million single nucleotide polymorphisms (SNPs) on the Illumina platform (Illumina, California). Genome-wide SNP homozygosity mapping using 979,427 autosomal SNPs was performed with HomozygosityMapper [4].
Sequencing and test analysis of mutations
DNA from four individuals, 3 affected (III:4, III:7 and III:10) and 1 unaffected sibling (III:9), was selected for whole exome sequencing (GATC, Germany). The exome of each individual was enriched with the SureSelect 38 Mb Human All Exon Kit (Agilent Technologies, Santa Clara), and sequenced on an Illumina Genome Analyser II platform. The single sequence reads were aligned to the hg18 reference genome with the Burrows-Wheeler Alignment tool version 0.5.7 [5] . Reads of inadequate sequence quality and potential PCR duplicates were discarded. The quality scores for the aligned reads were recalibrated using GATK [6] .
Regions containing clusters of SNPs (corresponding to local misalignment of reads around indels) were identified and the reads in these regions were realigned using GATK. Variants and indels were identified using SAMtools [7] .
The c.245A>G and c.1118A>G variants were validated by Sanger sequencing in available family members (Supplementary Table 3) . A control panel, comprising 186 control chromosomes from the Irish (n=48 alleles) and Irish Traveller (n=138 alleles) populations, was screened for each variant to determine its frequency in the general population.
A parametric two-point LOD score was calculated for the LARS c.245A>G and c.1118A>G variants using Merlin (http://www.sph.umich.edu/csg/abecasis/Merlin/tour/linkage.html) assuming a recessive model with full penetrance and a disease allele frequency of 0.0001.
The predicted impact and cross-species conservation of LARS p.K82R and p.Y373C were predicted using PolyPhen2. PolyPhen2 models amino acid substitutions using both structure and sequence information, comparing a property of the wild-type (ancestral, normal) allele and the corresponding property of the mutant (derived, disease-causing) allele. 
Small-interfering RNA transfection
Small-interfering RNA (siRNA) targeting LARS was purchased from Sigma (Sigma, St Louis). Cells were transfected in 6-well plates with either siRNA or scrambled control (100 nM) (Sigma) using Lipofectamine 2000 transfection reagent (9 μL) (Invitrogen, New York)
as per the manufacturer's instructions.
Mitochondrial functional studies
Mitochondrial function was assessed by measurement of mitochondrial mass, mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) using the probes 
Results
Homozygosity mapping and whole exome sequencing
To identify the locus responsible for the infantile hepatopathy in this family, we undertook a genome-wide SNP homozygosity mapping analysis. We identified two candidate loci; a major peak on chromosome 5 (141,640,648-149,027,979) and a minor peak on chromosome 15 (40,862,494-42,243,939) containing 62 and 40 genes respectively (Fig. 2a) . To identify the underlying causative mutation, DNA from four individuals, three affected and 1 unaffected sibling, was selected for exome sequencing. The exomes were sequenced to a mean coverage of 43-100 fold (Supplementary Table 4 ). On average 76,588 variants with a minimum SNP quality score of Q20 and 10x coverage were identified per individual.
Assuming a recessive model, we selected novel and rare homozygous non-synonymous variants that segregated with the hepatopathy and that were located within the two candidate linkage regions (Table 1) . Of the 126 homozygous segregating variants, 121 were reported to have a population frequency >1% (dbSNP130) and were considered unlikely to be disease- 
Frequency of LARS p.K82R and p.Y373C in the general population
To investigate the possibility that the LARS variants (c.245A>G and c.1118A>G) were previously unidentified polymorphisms in the Irish population, we sequenced both variants in 186 control chromosomes. The frequency of LARS c.245A>G (rs112954500) was 2.1%
(1/48 alleles) and 0% (0/138 alleles) in the Irish and Irish Traveller control groups respectively. In contrast, LARS c.1118A>G was not present in any of the 186 control chromosomes and has not been reported as a common polymorphic variant in dbSNP or the 1000 Genomes project.
Functional classification and evolutionary conservation of LARS p.K82R and p.Y373C
The Polyphen-2 classification tool was used to predict the functional consequences of each of the two missense mutations (K82R and Y373C) in LARS and to examine cross-species conservation. The K82R (lysine-to-arginine) variant is a conservative amino acid substitution and is predicted to be benign (Fig. 3a) . Furthermore, the residue at position 82 of the LARS protein shows low levels of conservation (61%) and the arginine residue observed in the patients is present in 15 species (Supplementary Table 5 ). In contrast, Y373C (tyrosine-tocysteine) is predicted to be potentially deleterious, is highly conserved across eukaryotic species (89%) and cysteine is only present in the blood fluke (Fig. 3a) .
Predicted effect of LARS p.Y373C on protein structure and function
The K82R substitution is located within a beta-turn structure of a region of LARS annotated as the nucleotidyl transferase superfamily (cl00015). While the effect of the K82R amino acid change on LARS folding cannot be anticipated (the protein structure for this region is not available), lysine-to-arginine is considered to be a conservative substitution, predicted to preserve the structure and functional properties of the protein [8]. However, K-to-R creates a candidate citrullination site. Therefore, while lysine-to-arginine is quite conservative in terms of the retained charge properties, the modification of arginine (+1) to citrulline (neutral) can change protein structure due to the loss of a positive charge. Examination of the annotated LARS protein structure shows that the Y373C mutation is located within the editing domain of LARS, known as connective peptide 1 (CP1), which extends from residue 260 to 509 (Fig.   3b ). Calculation of the mutation-induced energy changes predicted that the tyrosine-tocytosine mutation at position 373 destabilises the wild-type protein structure by 5.9 kJ/mol (Supplementary Table 6 ).
Impact of LARS knock-down on mitochondrial function in HEK293 cells
Although the patients in the current study have normal mitochondrial morphology, normal mitochondrial DNA content and normal respiratory enzyme complexes, the multisystem 
Discussion
We This observation suggests that the Y373C mutation does not occur frequently in the general population and supports the likelihood that it is a rare disease-causing mutation. Secondly, of all the possible amino acid substitutions, the large hydrophobic residues (tryptophan, tyrosine and phenylalanine) are replaced least often and the low mutability of these residues reflects their importance in forming the hydrophobic core of protein folds. The folding free energy is an important characteristic of a protein's stability and is directly related to its function.
Disease-causing point mutations often bring about a change in free energy which can affect protein stability. In the current study, LARS p.Y373C is predicted to destabilise the protein We analysed the leucine content of all proteins in the human genome. We hypothesised that proteins with a high requirement for leucine were the most likely to be affected in patients with mutations in LARS, the enzyme responsible for making leucine. We found that immunerelated proteins including the toll-like receptor family, interferons, various interleukins and other cytokines contain a very high percentage content of leucine. The observation that immune-related proteins have a high requirement for leucine correlates well with the phenotypic profile of the patients; the LARS mutation only appears penetrant/symptomatic when the patients are ill and require high levels of immunological proteins. In addition, we found that the phospholipid biosynthetic process is the most significantly enriched for proteins with a high percentage of leucine (corrected p value = 0.0017) (Supplementary Table   7 ). Liver biopsies of the patients show the presence of large fat deposits in the liver and defects in phospholipid biosynthesis have been linked to fatty liver disease. Given the high recurrence risk in endogamous Irish Traveller families, identification of the causative mutation in these patients will have considerable implications for their families both in terms of prognostic advice and genetic counselling.
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Supplementary
Multiple species alignment was performed using PolyPhen2 for the amino acids at positions 82 and 373 of the LARS protein. The residues at positions 82 and 373 are conserved in 58/96 and 78/88 species respectively. Proteins with ≥20% leucine content were analysed using WebGestalt [2] to identify biological processes that are significantly enriched for proteins with a high percentage leucine content. A hypergeometric analysis was applied with stringent Bonferonni correction to adjust for multiple testing. Biological processes with an adjusted p value < 0.05 are listed.
